These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 7833105

  • 1. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study.
    Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, Trovò MG, Nascimben O, Sibau A, Talamini R.
    Eur J Cancer; 1994; 30A(10):1474-8. PubMed ID: 7833105
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 15; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 4. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr 15; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 5. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 15; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 6. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 7. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan 15; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 8. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 15; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 9. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC.
    J Clin Oncol; 1996 Mar 15; 14(3):806-13. PubMed ID: 8622028
    [Abstract] [Full Text] [Related]

  • 10. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T.
    Cancer; 1993 Sep 01; 72(5):1597-601. PubMed ID: 8394202
    [Abstract] [Full Text] [Related]

  • 11. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB.
    Int J Radiat Oncol Biol Phys; 1998 Mar 15; 40(5):1039-47. PubMed ID: 9539558
    [Abstract] [Full Text] [Related]

  • 12. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer.
    Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, Intini C.
    J Chemother; 1993 Oct 15; 5(5):344-7. PubMed ID: 8106908
    [Abstract] [Full Text] [Related]

  • 14. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
    Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R.
    Semin Oncol; 1994 Jun 15; 21(3 Suppl 6):31-5. PubMed ID: 8052871
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun 15; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 15; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 17. Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
    Casadio M, Lelli G, Giordani S, Boltri B, Blotta A, Busutti L, Ramini R, Falcone F, Pannuti F.
    J Chemother; 1990 Jun 15; 2(3):199-202. PubMed ID: 2166145
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct 15; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
    Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K.
    J Natl Cancer Inst; 1991 Jun 19; 83(12):855-61. PubMed ID: 1648142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.